Ligand Pharmaceuticals LGND · NASDAQ
$306.20 +2.41% (+$7.20)
Summary
36 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 20 USD is left as net profit.
- Revenue grew by 11% a year over the last 3 years.
What to watch
- Repaying its net debt would take 8.5 years of operating profit.
- The share price is above the Bulios Fair Price.
- It earns only 1.4 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 119.0 USD for 1 USD of yearly profit. Over the last five years it was 28.1 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 10% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 9.0%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales -7.1 USD
- Research and development 9.1 USD
- Sales and administration 86 USD
- Taxes and other -8.4 USD
- Net profit 20 USD
Net profit, industry median (Biotechnology) -9.2 USD
Out of every 100 USD of revenue, 20 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 8.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 4
- Sell 1
Today's price within the analysts' price targets
The average target of $342 is 12% above today's price. 72% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Royalty 33%
- Intangible Royalty Assets 27%
- Contract Revenue 14%
- Material Sales, Captisol, Core 8.1%
- Royalty, Kyprolis 7.2%
- Other 12%
By region
The company reports no revenue by region.
Royalty brings in 33% of revenue. Material Sales, Captisol, Core grew fastest, by 35% a year.
Segments in detail